Year: 2020
Type: review
Abstract: BACKGROUND: The panel of fluid- and imaging-based biomarkers available for neurodegenerative disease research is growing and has the potential to close important gaps in research and the clinic. With this growth and increasing use, appropriate implementation and interpretation are paramount. Various biomarkers feature nuanced differences in strengths, limitations, and biases that must be considered when investigating disease etiology and clinical utility. For example, neuropathological investigations of Alzheimer's disease pathogenesis can fall in disagreement with conclusions reached by biomarker-based investigations. Considering the varied strengths, limitations, and biases of different research methodologies and approaches may help harmonize disciplines within the neurodegenerative disease field. PURPOSE OF REVIEW: Along with separate review articles covering fluid and imaging biomarkers in this issue of Alzheimer's Research and Therapy, we present the result of a discussion from the 2019 Biomarkers in Neurodegenerative Diseases course at the University College London. Here, we discuss themes of biomarker use in neurodegenerative disease research, commenting on appropriate use, interpretation, and considerations for implementation across different neurodegenerative diseases. We also draw attention to areas where biomarker use can be combined with other disciplines to understand issues of pathophysiology and etiology underlying dementia. Lastly, we highlight novel modalities that have been proposed in the landscape of neurodegenerative disease research and care.
Source: Alzheimer s Research & Therapy
Authors: Alexander J. Ehrenberg, Ayesha Khatun, Emma Coomans, Matthew J. Betts, Federica Capraro, Elisabeth H. Thijssen, Konstantin Senkevich, Tehmina Bharucha, Mehrsa Jafarpour, Peter N. E. Young, William Jagust, Stephen F. Carter, Tammaryn Lashley, Lea T. Grinberg, Joana B. Pereira, Niklas Mattsson-Carlgren, Nicholas J. Ashton, Jörg Hanrieder, Henrik Zetterberg, Michael Schöll, Ross W. Paterson
Institutions: University of California, San Francisco, University of California, Berkeley, UCL Queen Square Institute of Neurology, University College London, Amsterdam Neuroscience, Amsterdam UMC Location Vrije Universiteit Amsterdam, German Center for Neurodegenerative Diseases, Otto-von-Guericke-Universität Magdeburg, The Francis Crick Institute, Amsterdam University Medical Centers, First Pavlov State Medical University of St. Petersburg, Kurchatov Institute, Petersburg Nuclear Physics Institute, University of Oxford, Lund University, University of Gothenburg, Lawrence Berkeley National Laboratory, University of Cambridge, University of Manchester, National Hospital for Neurology and Neurosurgery, Universidade de São Paulo, Global Brain Health Institute, Karolinska Institutet, King's College London, South London and Maudsley NHS Foundation Trust, Sahlgrenska University Hospital, UK Dementia Research Institute
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,170
Funders: Francis Crick Institute, Amsterdam University Medical Centers, National Institute for Health and Care Research, King's College London, University College London, University of Oxford, Lunds Universitet, Hjärnfonden, Karolinska Institutet, Knut och Alice Wallenbergs Stiftelse, Vetenskapsrådet, Universidade de São Paulo, Sahlgrenska Universitetssjukhuset, Göteborgs Universitet, Alzheimerfonden, UK Dementia Research Institute, National Institutes of Health, University of California, San Francisco, Sahlgrenska Akademin, Medicinska Fakulteten, Lunds Universitet, Wallenberg Centre for Molecular and Translational Medicine, National Institute on Aging, National Institute of Neurological Disorders and Stroke, Nuclear Physics, Lawrence Berkeley National Laboratory, H2020 European Research Council
Awards: Linking tau proteostasis with neuronal activity in FTD, G6069138294, G6657799732, Pathways to Alzheimer's disease, G7198253607, What determines amyloid beta aggregation and toxicity in Alzheimer’s disease?, Neuropathological changes underlying clinical heterogeneity in Alzheimer dise, New Approaches to Dementia Heterogeneity
OpenAlex ID: W3027478827
